LXRX (Lexicon Pharmaceuticals) Marketable Securities: $132.57 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LXRX Lexicon Pharmaceuticals Inc LXRX
39 GF Score
Price $2.34
! 5 Warning Signs
View Full Analysis

What is Lexicon Pharmaceuticals Marketable Securities?

Lexicon Pharmaceuticals LXRX +0.86% 39 Marketable Securities is $132.57 Mil as of Mar. 2026. GuruFocus rates LXRX with a GF Score™ of 39/100. The stock has 5 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Lexicon Pharmaceuticals's Marketable Securities for the quarter that ended in Mar. 2026 was $132.57 Mil.

Lexicon Pharmaceuticals's annual Marketable Securities increased from Dec. 2023 ($147.56 Mil) to Dec. 2024 ($171.30 Mil) but then declined from Dec. 2024 ($171.30 Mil) to Dec. 2025 ($61.90 Mil).

Lexicon Pharmaceuticals  (NAS:LXRX) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Lexicon Pharmaceuticals Marketable Securities Related Terms

Lexicon Pharmaceuticals Marketable Securities Historical Data

* Premium members only.

The historical data trend for Lexicon Pharmaceuticals's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lexicon Pharmaceuticals Marketable Securities Chart

Lexicon Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.68 92.01 147.56 171.30 61.90

Lexicon Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 131.95 117.64 66.29 61.90 132.57
LXRX
39GF Score
Lexicon Pharmaceuticals Inc LXRX
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lexicon Pharmaceuticals Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $132.57 Mil mean?
Lexicon Pharmaceuticals (LXRX) has a Marketable Securities of $132.57 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Lexicon Pharmaceuticals and its competitors.
Is Lexicon Pharmaceuticals' Marketable Securities too high?
Lexicon Pharmaceuticals' current Marketable Securities is $132.57 Mil. Overall, Lexicon Pharmaceuticals has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Lexicon Pharmaceuticals' Marketable Securities compare to EYPT and OLMA?
Lexicon Pharmaceuticals' Marketable Securities of $132.57 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Lexicon Pharmaceuticals and its competitors. Lexicon Pharmaceuticals's current Marketable Securities is $132.57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lexicon Pharmaceuticals stock overvalued right now?
Lexicon Pharmaceuticals (LXRX) has a current Marketable Securities of $132.57 Mil. The current Marketable Securities is $132.57 Mil. Lexicon Pharmaceuticals' overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Lexicon Pharmaceuticals (LXRX), the current Marketable Securities is $132.57 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lexicon Pharmaceuticals Business Description

Address 2445 Technology Forest Boulevard, 11th Floor, The Woodlands, TX, USA, 77381
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
39GF Score

Get the complete analysis for LXRX

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.34
Price